Gravity shift: What pharma MNCs can learn from generic companies

Abstract

The pharmaceutical industry in Asia is gearing up to be at the center of global market, and most expect that the shift has already started. Asia has its own set of challenges and risks and demands a “whole New Strategy Approach” for all emerging markets to compensate internal factors of MNCs limiting the success in the Asian markets. Some key challenges are: IPRs, corruption, regulated pricing pressures, affordability, and lack of knowledge of local business environment and culture.Generic/domestic companies have been performing so well in the same environment.